Jamie E. Chaft
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Diagnosis and Treatment 76
- Lung Cancer Treatments and Mutations 61
- Metastasis and carcinoma case studies 3
- Oncology 83
- Cancer Immunotherapy and Biomarkers 72
- Lung Cancer Research Studies 7
- Co-authors
- Mark G. Kris (43 shared papers)Matthew David Hellmann (24 shared papers)Gregory J. Riely (13 shared papers)Marc Ladanyi (11 shared papers)Maria Arcila (10 shared papers)Camelia S. Sima (12 shared papers)Valerie W. Rusch (20 shared papers)Andrew J. Plodkowski (7 shared papers)
- Journals
- Journal of Thoracic Oncology (27 papers)Annals of Oncology (12 papers)Journal of Clinical Oncology (10 papers)Clinical Cancer Research (10 papers)Journal of Thoracic and Cardiovascular Surgery (10 papers)
- Partner nations
- United StatesJapanAustralia
In The Last Decade
Jamie E. Chaft
172 papers receiving 24.2k citations
Jamie E. Chaft's Hit Papers
Peers
Comparison fields: 5 of 124
- Oncology 12.5k
- Pulmonary and Respiratory Medicine 9.9k
- Cancer Research 2k
- Otorhinolaryngology 247
- Immunology 800
Countries citing papers authored by Jamie E. Chaft
This map shows the geographic impact of Jamie E. Chaft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie E. Chaft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie E. Chaft more than expected).
Fields of papers citing papers by Jamie E. Chaft
This network shows the impact of papers produced by Jamie E. Chaft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie E. Chaft. The network helps show where Jamie E. Chaft may publish in the future.
Co-authors
The 25 scholars most cited alongside Jamie E. Chaft, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 182 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types Hit paper breakdown → | 2019 | 3043 |
| 2 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer Hit paper breakdown → | 2018 | 1663 |
| 3 | Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Hit paper breakdown → | 2018 | 1163 |
| 4 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2016 | 946 |
| 5 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 861 |
| 6 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 852 |
| 7 | Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer Hit paper breakdown → | 2018 | 745 |
| 8 | Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 711 |
| 9 | Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis Hit paper breakdown → | 2014 | 703 |
| 10 | Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Hit paper breakdown → | 2016 | 547 |
| 11 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies Hit paper breakdown → | 2017 | 541 |
| 12 | Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study Hit paper breakdown → | 2016 | 533 |
| 13 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint Hit paper breakdown → | 2014 | 522 |
| 14 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 498 |
| 15 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Hit paper breakdown → | 2013 | 495 |
| 16 | 2018 | 441 | |
| 17 | EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Hit paper breakdown → | 2013 | 421 |
| 18 | Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas Hit paper breakdown → | 2012 | 417 |
| 19 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers Hit paper breakdown → | 2021 | 390 |
| 20 | Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design Hit paper breakdown → | 2011 | 368 |
About Jamie E. Chaft
Jamie E. Chaft is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiation and Radiology, Nuclear Medicine and Imaging, having authored 182 papers that have together received 24.6k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (76 papers), Cancer Immunotherapy and Biomarkers (72 papers), Lung Cancer Treatments and Mutations (61 papers), Cancer Genomics and Diagnostics (8 papers), Lung Cancer Research Studies (7 papers), Metastasis and carcinoma case studies (3 papers), Chromatin Remodeling and Cancer (3 papers) and Advanced Radiotherapy Techniques (3 papers). The work is most often cited by research in Oncology (12.5k citations), Pulmonary and Respiratory Medicine (9.9k citations), Cancer Research (2k citations), Otorhinolaryngology (247 citations) and Immunology (800 citations). Jamie E. Chaft has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include Mark G. Kris, Matthew David Hellmann, Gregory J. Riely, Marc Ladanyi, Maria Arcila, Camelia S. Sima, Valerie W. Rusch, Andrew J. Plodkowski, William David Travis and Maureen Frances Zakowski. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Journal of Thoracic and Cardiovascular Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.